Duncan McKechnie insider trades: Vertex Pharmaceuticals Inc / Ma (VRTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Duncan reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | VRTX | ↓ Sell | 1,541 | $519.00 | $800K | Direct | Jul 7, 2026 (5d) |
| Mar 4, 2026 | VRTX | ↓ Sell | 2,437 | $475.30 | $1.2M | Direct | Mar 6, 2026 (2d) |
| Feb 25, 2026 | VRTX | ↓ Sell | 4,910 | $487.65 | $2.4M | Direct | Feb 26, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VRTX insiders
Open-market trades in the last 12 months
About Duncan McKechnie's insider trades
Duncan McKechnie is EVP, Chief Commercial Officer at Vertex Pharmaceuticals Inc / Ma (VRTX). Since Feb 25, 2026, Duncan has reported no open-market purchases and 3 sales worth $4.4M on SEC Form 4. In the last 12 months: 3 sales ($4.4M).
Their filings also include shares withheld for taxes (4 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VRTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.